{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-116307","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2025-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.105459+00:00","generated_at":"2026-05-16T15:55:25.819477+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Cadrenal Therapeutics appoints Dr. Lee Golden to Board of Directors","bullets":["Dr. Lee Scott Golden appointed independent Class II director effective Nov 24, 2025; term expires at 2027 annual meeting.","Golden is EVP and CMO of PTC Therapeutics (PTCT) with 25+ years in cardiovascular and hematologic drug development.","Golden serves on Science and Technology Committee; receives $35,000 annual fee plus equity awards.","Appointment aligns with Cadrenal's focus on advancing tecarfarin for anticoagulation unmet needs."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-116307","json":"https://secwatch.observer/filing/0001213900-25-116307.json","markdown":"https://secwatch.observer/filing/0001213900-25-116307.md","text":"https://secwatch.observer/filing/0001213900-25-116307.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390025116307/0001213900-25-116307-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390025116307/ea0267189-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:55:25.819477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}